Literature DB >> 9199626

Significance of peritoneal washings in gynecologic oncology. The experience with 901 intraoperative washings at an academic medical center.

S Mathew1, Y S Erozan.   

Abstract

OBJECTIVE: Peritoneal washings are routinely performed during gynecologic surgery. The presence or absence of malignant cells in washings helps determine the stage of the malignancy. However, the efficacy of this procedure has not been studied recently.
DESIGN: All intraoperative washings for gynecologic disease at our hospital from 1992 through 1994 (901 cases) were reviewed. Of these, 380 were gynecologic malignancies that were reviewed for changes in staging based on the presence of malignant cells.
RESULTS: Histologically, 380 cases were gynecologic malignancies, 521 benign, 79 nongynecologic, and 25 had no accompanying surgical pathology. Of the malignancies, 125 had a diagnosis of cancer on washings. In 12 cases (3.1%), a change in stage resulted.
CONCLUSIONS: In a small but significant number of cases, malignant cells in the washings changed postoperative staging, impacting therapeutic measures and prognosis for these patients greatly. Peritoneal washings remain a simple yet effective tool in the evaluation and management of gynecologic malignancies.

Entities:  

Mesh:

Year:  1997        PMID: 9199626

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  3 in total

Review 1.  Diagnostic Cytopathology of Peritoneal Washings.

Authors:  Rosemary E Zuna
Journal:  Cytojournal       Date:  2022-02-28       Impact factor: 2.345

Review 2.  The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.

Authors:  F Blok; E M Roes; G J L H van Leenders; H J van Beekhuizen
Journal:  BMC Cancer       Date:  2016-01-14       Impact factor: 4.430

3.  Diaphragmatic smears are not of additional benefit in the detection of peritoneal spread in gynecological cancers.

Authors:  Celine Montavon; Uzma Mirza; Andre Fedier; Andreas Schoetzau; Rosanna Zanetti Dällenbach; Viola Heinzelmann-Schwarz
Journal:  Exp Ther Med       Date:  2018-03-13       Impact factor: 2.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.